This report describes how new techniques for measuring erythropoietin and erythropoietic function have been used to analyse the mode of action of oxymetholone during treatment of a patient with hypoplastic anaemia.
Case report
A 22-year-old woman had chronic idiopathic hypoplastic anaemia which partially responded to oxymetholone treatment. She was first seen at the age of 5 years, when her blood count showed: haemoglobin 4 0 g/dl, neutrophils 0-5 x 109/1 (500/mm3), and platelet count 73 x 109/1 (73 000/mm3). Marrow cellularity was normal. Treatment consisted of blood transfusions and a short course of prednisone, the prednisone producing no benefit. At the age of 9 a spontaneous remission occurred (haemoglobin 12-5 g/dl, neutrophils 3-5 x 109/1 (3500/mm3), and platelet count 180 x 109/1 (180 000/mm3)).
She remained well until the present hospital attendance, when pancytopenia was found to have recurred (haemoglobin 7-9 g/dl, neutrophils 1.0 x 109/1 (1000/mm3), and platelets 17 x 109/1 (17 000/mm3)). Pretreatment marrow examination showed normal cellularity and normoblastic erythropoiesis with slight evidence of dyserythropoiesis. Results of other investigations did not contribute to the diagnosis. Despite the severe pancytopenia her symptoms were confined to occasional petechial haemorrhages. Because no spontaneous improvement occurred during the next three months oxymetholone was given at an initial daily dose of 3 mg/kg. During the next two months her haemoglobin concentration rose progressively to 10 5-12-5 g/dl. Platelet and neutrophil counts showed no significant changes. The results of haematological studies are shown in the table. Because of the lack of symptomatic benefit oxymetholone treatment was reduced, then discontinued. Almost Oxymetholone increased urinary erythropoietin excretion in 70% of a series of patients with bone marrow failure, but only 230' showed improvement in their erythropoietic status.5 An increase in the already greatly increased serum erythropoietin levels would not be expected to produce significant improvement in our patient. Although the serum erythropoietin concentration was not measured immediately after the start of oxymetholone treatment, erythropoietin concentrations during the oxymetholone-maintained remission were within the normal range. A rise in erythropoietin level followed the development of anaemia after withdrawal of oxymetholone. Therefore remission in this patient was not sustained by means of increased erythropoietin levels. Ferrokinetic measurements showed that the anaemia results from an increased amount of ineffective erythropoiesis accompanied by a reduction in mean red-cell lifespan. The observation that marrow erythroid cellularity was with normal limits agreed with the finding that total marrow iron turnover was normal. During oxymetholone treatment total marrow activity was unchanged, but the proportion of ineffective erythropoiesis fell to normal. This allowed an increased red cell production rate, and, although the haemolytic component continued, the haemoglobin concentration improved.
These results point to changes occurring in the maturing erythroblast compartment and would be incompatible with an oxymetholone effect on erythropoietin-responsive stem cells. Such a mechanism as that described above, which produces a small but important increase in ineffective red cell production, would be in keeping with the slow progressive improvement during oxymetholone treatment.
